Why is the Volpara share price rocketing 13% today?

This health technology share is catching the eye with a very strong gain on Tuesday.

| More on:
A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is taking off on Tuesday.

In afternoon trade, the health technology company's shares are up 13% to 72.5 cents.

Why is the Volpara share price rocketing?

Investors have been buying the company's shares today after responding very positively to its quarterly update.

According to the release, for the three months ended 30 September, Volpara reported record cash receipts of NZ$11.5 million. This was up 32% over the prior corresponding period.

In addition, the company finished the period with contracted annual recurring revenue (CARR) of ~US$28.4 million (~NZ$46.3 million), which is up over US$1.2 million since the end of June.

Also growing was Volpara's annual recurring revenue (ARR), which is now ~US$22.5 million (~NZ$36.6 million). This is up from US$21.5 million in the prior quarter.

But arguably the most important number on this release, and the one giving the Volpara share price the biggest lift, was its cash flow.

The company reported positive net operating cash flow of NZ$1.2 million for the quarter. This is the fourth consecutive quarter of positive net operating cash flow. Impressively, this means Volpara achieved its cash flow target 18 months ahead of plan.

In light of this achievement, the company is no longer required to provide Appendix 4C quarterly reporting updates. However, management advised that it remains committed to providing regular operational and financial updates to shareholders and will therefore release business updates periodically.

A milestone quarter

Volpara CEO's and Managing Director, Teri Thomas, appeared to be rightfully pleased with the quarter. Thomas said:

What a milestone quarter for us! I'm delighted to see current customers, happy with our software, expand their use of Volpara to save even more families from cancer. We had a record number of contracts up for renewal and customers have chosen to expand and extended their contracts with us for longer, with more software than ever before. Our record cash receipts reflect the positive impact we have on families, as happy customers pay their bills.

Our growth and financial strength, approaching US$100M TCV, allows us to turn increasingly to growth endeavours like a brand-new product, called Quiver, due out next year. Leveraging our Analytics platform, this new product provides administrative simplification for mammography centres so they can spend more time with patients. We do good and we do it well and that is reflected in this positive quarter.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Volpara Health Technologies. The Motley Fool Australia has positions in and has recommended Volpara Health Technologies. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a woman puts a pen to her mouth as she smiles slightly while checking an old book style diary/calendar.
Healthcare Shares

Dates that could move the NIB share price in 2024

NIB shares investors, get out your 2024 diaries...

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

ASX 300 healthcare stock Sigma halted amid rumours of blockbuster Chemist Warehouse deal

Is Chemist Warehouse finally joining the ASX?

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 200 healthcare stock is surging 8% on record sales

This medical device company's sales growth was strong in November.

Read more »

Person with a handful of Australian dollar notes, symbolising dividends.
Dividend Investing

Which ASX 200 healthcare share will pay the best dividend yield in FY24?

Healthcare stocks are a traditional defensive play in challenging economic times.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

Can NIB shares reach $9 by Christmas?

It has been a good few weeks for shareholders. Can the stock keep going?

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Broker Notes

CSL shares up 15% in 5 weeks amid two hedge funds placing opposing bets

Let's see what these funds have to say about CSL shares.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Why is the Mesoblast share price sinking 25% on Tuesday?

This biotech is being sold off today. But why?

Read more »

Scientist with headache, stress and fatigue with woman, overworked with overtime for science breakthrough. Medical research, scientific innovation and senior female, burnout and migraine in lab.
Healthcare Shares

Why is the Mesoblast share price in a trading halt?

Is Mesoblast raising funds again? Let's find out.

Read more »